ASXL1 and chronic myelomonocytic leukemia: A patient-derived xenograft (PDX) mouse model experiment using a human chronic myelomonocytic leukemia (CMML) cell line demonstrated that concurrent mutations of RUNX1 and ASXL1 promoted cell renewal in bone marrow and leukemic transformation, which was induced by the augmented production of hypoxia-inducible factor 1 subunit alpha (HIF1-α) and the consequent upregulation of the inhibitor of DNA binding 1 (ID1) and AKT1 signaling [87].